Clinical trial
Optimal Ablation Endpoint for Longstanding Persistent Atrial Fibrillation: a Randomized Prospective Study
NCT02929836 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Optimal Ablation Endpoint for Longstanding Persistent Atrial Fibrillation: a Randomized Prospective Study
- Lead sponsor
- Shanghai Chest Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- May 31, 2016
- Completion date
- October 31, 2018
- Enrollment
- 450 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.